US stock BNB Treasury Company WINT was delisted by Nasdaq due to violations, with its stock price dropping another 77%, leaving a market value of only 3 million dollars

ChainCatcher news reports that according to market data, the US stock BNB Treasury company Windtree Therapeutics (WINT) received a notification from Nasdaq in 2025 due to its stock price remaining below $1 for too long (Rule 5550(a)(2)). After multiple reverse splits and not meeting the usual grace period, its common stock will be delisted from the Nasdaq Capital Market and transferred to OTC market trading on August 21. This news caused its stock price to start declining early this morning, ultimately closing down 77.21%, with a market value of only $3.152 million.

It is noteworthy that WINT's stock price has maintained a textbook-like "zeroing out" trend for nearly a year. On August 22 last year, the stock price was $517.5, and it has since accumulated a decline of 99.98%. The opening price on February 21 this year was $4.68, and it has since accumulated a decline of 97.8%. After announcing the BNB Treasury strategy a month ago, the stock experienced a significant increase in trading volume over several trading days (including a few days before the announcement), ultimately reaching a recent high of $1.28 on July 18, and then began a one-sided decline, accumulating a decline of 91.4% to date.

It is reported that Windtree Therapeutics is a clinical-stage biopharmaceutical and medical device company, with several medical projects still in clinical stages far from commercialization. According to the latest data, the company's net income for the most recent quarter was -$10.64 million, compared to -$4.04 million in the previous quarter, representing a 163.04% increase in losses. The company initially announced on July 16 the launch of the BNB Treasury strategy, aiming to raise $60 million through a securities subscription. On July 25, it announced that it had signed a new financing agreement for $520 million to purchase BNB.